Iovance Biotherapeutics, Inc. (IOVA) stock
IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.53−0.02 (-0.26%)
Close on Nov 17, 2026Market cap $3.41BP/E –Yield –
Iovance Biotherapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Iovance Biotherapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $267.72M, down 8.3% year over year. For fiscal 2025 it was $300.27M, up 8.7% from the year before. Over ten years it grew 34.5% a year on average. The highest annual figure on record is $333.19M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $300.27M | +8.7% |
| FY2024 | Dec 31, 2024 | $276.23M | -17.1% |
| FY2023 | Dec 31, 2023 | $333.19M | +13.0% |
| FY2022 | Dec 31, 2022 | $294.78M | +13.8% |
| FY2021 | Dec 31, 2021 | $259.04M | +28.4% |
| FY2020 | Dec 31, 2020 | $201.73M | +21.5% |
| FY2019 | Dec 31, 2019 | $166.02M | +66.3% |
| FY2018 | Dec 31, 2018 | $99.83M | +39.4% |
| FY2017 | Dec 31, 2017 | $71.62M | +165.8% |
| FY2016 | Dec 31, 2016 | $26.94M | +74.1% |
| FY2015 | Dec 31, 2015 | $15.47M | +301.9% |
| FY2014 | Dec 31, 2014 | $3.85M | +78.7% |
| FY2013 | Dec 31, 2013 | $2.15M | +30.1% |
| FY2012 | Dec 31, 2012 | $1.66M | -5.7% |
| FY2011 | Dec 31, 2011 | $1.76M | +923.7% |
| FY2010 | Dec 31, 2010 | $171.48K | – |
| FY2009 | Dec 31, 2009 | $0 | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $58.85M | -24.5% |
| Q1 FY2026 | Mar 31, 2026 | $62.49M | -17.7% |
| Q4 FY2025 | Dec 31, 2025 | $71.20M | +0.3% |
| Q3 FY2025 | Sep 30, 2025 | $75.17M | +12.1% |
| Q2 FY2025 | Jun 30, 2025 | $77.93M | +25.5% |
| Q1 FY2025 | Mar 31, 2025 | $75.97M | -4.8% |
| Q4 FY2024 | Dec 31, 2024 | $71.01M | -7.3% |
| Q3 FY2024 | Sep 30, 2024 | $67.04M | -23.4% |
| Q2 FY2024 | Jun 30, 2024 | $62.08M | -28.1% |
| Q1 FY2024 | Mar 31, 2024 | $79.78M | -3.6% |
| Q4 FY2023 | Dec 31, 2023 | $76.59M | -4.9% |
| Q3 FY2023 | Sep 30, 2023 | $87.53M | +20.7% |
| Q2 FY2023 | Jun 30, 2023 | $86.35M | +17.6% |
| Q1 FY2023 | Mar 31, 2023 | $82.73M | +21.1% |
| Q4 FY2022 | Dec 31, 2022 | $80.57M | +6.6% |
| Q3 FY2022 | Sep 30, 2022 | $72.50M | +10.9% |
| Q2 FY2022 | Jun 30, 2022 | $73.41M | +18.2% |
| Q1 FY2022 | Mar 31, 2022 | $68.30M | +22.1% |
| Q4 FY2021 | Dec 31, 2021 | $75.62M | +44.2% |
| Q3 FY2021 | Sep 30, 2021 | $65.36M | +51.8% |
| Q2 FY2021 | Jun 30, 2021 | $62.12M | +26.1% |
| Q1 FY2021 | Mar 31, 2021 | $55.95M | -1.8% |
| Q4 FY2020 | Dec 31, 2020 | $52.45M | -3.3% |
| Q3 FY2020 | Sep 30, 2020 | $43.05M | +3.5% |
| Q2 FY2020 | Jun 30, 2020 | $49.27M | +25.4% |
| Q1 FY2020 | Mar 31, 2020 | $56.95M | +84.3% |
| Q4 FY2019 | Dec 31, 2019 | $54.24M | +97.8% |
| Q3 FY2019 | Sep 30, 2019 | $41.58M | +48.8% |
| Q2 FY2019 | Jun 30, 2019 | $39.30M | +60.1% |
| Q1 FY2019 | Mar 31, 2019 | $30.91M | +55.2% |
| Q4 FY2018 | Dec 31, 2018 | $27.42M | +32.5% |
| Q3 FY2018 | Sep 30, 2018 | $27.95M | +67.6% |
| Q2 FY2018 | Jun 30, 2018 | $24.55M | +31.7% |
| Q1 FY2018 | Mar 31, 2018 | $19.91M | +27.7% |
| Q4 FY2017 | Dec 31, 2017 | $20.70M | +112.5% |
| Q3 FY2017 | Sep 30, 2017 | $16.68M | +96.7% |
| Q2 FY2017 | Jun 30, 2017 | $18.65M | – |
| Q1 FY2017 | Mar 31, 2017 | $15.59M | – |
| Q4 FY2016 | Dec 31, 2016 | $9.74M | – |
| Q3 FY2016 | Sep 30, 2016 | $8.48M | – |
See a number that looks wrong?